poisar

Stocks · News reference

Oragenics Receives NYSE American Approval of Compliance Plan and Extension Through February 2028

Fiscal.ai

Oragenics, Inc. announced that NYSE Regulation has accepted its compliance plan, granting the company an extension until February 25, 2028, to regain compliance with continued listing standards.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARSEC EDGAR

    8-K filing — ORAGENICS INC (OGEN)

    Filed: 2026-09-16 AccNo: 0001493152-26-042843 Size: 7 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

  2. BenzingaBenzinga Newsdesk

    Oragenics Advances Phase IIa Trial With 9 Participants Dosed; Recieved NYSE American Non Compliance Letter, Has 45 Days From Receipt Of The Deficiency Letter Within Which To Submit A Plan To Regain Compliance With The Continued Listing Standards

    Oragenics, Inc. (NYSE:OGEN), a clinical-stage biopharmaceutical company developing brain-targeted therapeutics through its proprietary intranasal delivery platform, today provided an update on its Phase IIa clinical